SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys is experiencing a massive surge in retail interest and trading volume, with the community actively speculating about a short squeeze similar to past meme stock movements. Investors are highlighting the company's dividend yield and buyout potential as reasons to hold, while social media chatter focuses on aggressive buying to combat short-side institutional pressure.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense selling pressure as shares drop toward two-year lows, driven by community concerns over consistent dilution and the stock's weakening correlation with Bitcoin. Investors are heavily debating whether the current price represents a generational buying opportunity or a structural collapse, with many focused on the stock's critical support levels and the risk of further capitulation.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber Technologies is currently seeing heightened social media activity driven by reports that the company has implemented spending caps on internal AI coding tools after exhausting its annual budget, alongside ongoing investor chatter about institutional accumulation. While some retail traders express frustration with recent price consolidation and daily volatility, others remain bullish, citing the company's platform growth, robust free cash flow, and potential tailwinds from upcoming major sporting events.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is facing significant volatility ahead of its first post-IPO earnings report, with the community closely tracking a massive upcoming insider share unlock and the stock's high valuation relative to its revenue. Investors are heavily divided, with some betting on a squeeze fueled by major partnerships with OpenAI and AWS, while others argue that the high price-to-sales ratio and reliance on a limited customer base suggest a potential sharp repricing.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as the community closely watches recent insider buying by CEO Kevin Tang, which has fueled speculation regarding a potential buyout or major strategic shift for the company. Shareholders are actively debating the timing of upcoming trial results and patent updates, with many expressing long-term optimism despite the stock's recent price volatility.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning, Inc. (GLW) is trending due to its pivotal role in AI infrastructure, with investors focusing on the company’s critical partnerships with major hyperscalers to supply the optical fiber and connectivity hardware essential for data center scaling. The community is actively debating the stock’s potential as a structural ‘picks and shovels’ play in the photonics and optics revolution, while closely monitoring its recent price volatility and relative strength against the broader market.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is trending as investors debate whether the stock is a cyclical mortgage play hindered by rising interest rates or a long-term AI-driven housing platform poised for a structural repricing. Community sentiment remains deeply divided, with some traders focused on short-term price volatility and potential institutional accumulation, while others express frustration over stagnant performance compared to IPO levels and ongoing market uncertainty regarding housing policy.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential index-fund buying ahead of the upcoming Russell 1000 reconstitution. The community is actively discussing the company's prospects for global expansion, anticipated clinical data, and the ongoing battle with significant short interest.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors brace for high-stakes earnings, with the community intensely debating whether the stock's parabolic growth is fully priced in or if the structural memory super-cycle justifies further upside. Sentiment is sharply divided between bulls expecting a blowout report to trigger a massive breakout and bears positioning for a post-earnings sell-off due to extreme volatility and concerns over unsustainable capital expenditures.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is surging as investors react to a major new partnership with Tesla and Renew Home, which aims to leverage millions of residential solar and battery systems to create a massive virtual power plant for data centers and AI energy needs. The community is actively debating whether this infrastructure-light model will trigger a long-term valuation re-rating or if the stock remains susceptible to volatility and broader sector headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Genmab Presents Promising Epcoritamab Data In Elderly DLBCL Patients

(RTTNews) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are not eligible for anthracycline-based chemotherapy...

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or...

Genmab Reports Epcoritamab Benefits Across Relapsed Follicular Lymphoma Subgroups

(RTTNews) - Genmab A/S (GMAB) on Thursday presented new subgroup data from the Phase 3 EPCORE FL-1 trial showing that epcoritamab in combination with rituximab and lenalidomide (R2) delivered consistent efficacy and a manageable safety profile across multiple patient subgroups wi...

Genmab Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Genmab A/S (Nasdaq: GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE FL-1 trial, evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, in combination with rituximab and lenalidomide (epcoritamab + R2) in adult patients with...

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Genmab A/S (Nasdaq: GMAB) announced today that 23 abstracts, including 20 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 29-June 2...

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and...

What is HC Wainwright's Forecast for Genmab A/S Q2 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for shares of Genmab A/S in a report released on Thursday, April 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings o...

Oppenheimer Asset Management Inc. Acquires 48,894 Shares of Genmab A/S Sponsored ADR $GMAB

Oppenheimer Asset Management Inc. raised its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 15.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 364,756 shares of the company's stock after...

Genmab A/S (OTCMKTS:GNMSF) Sees Strong Trading Volume  - Still a Buy?

Genmab A/S (OTCMKTS:GNMSF) Sees Large Volume Increase - Should You Buy...

HC Wainwright Has Lowered Expectations for Genmab A/S (NASDAQ:GMAB) Stock Price

HC Wainwright reduced their price target on Genmab A/S from $40.00 to $38.00 and set a "buy" rating for the company in a report on Thursday...

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab - ADR

Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$25.93
Prev Close	$25.94
Open	$26.05
Dividend Yield	0.00%
50-Day Moving Average	$26.42
Beta	0.66
Avg. Volume	2.24M
PE Ratio	19.37

52-Week High	$35.43
52-Week Low	$20.23
Market Capitalization	$15.43B
EPS (Annual)	$1.55
Price to Book	2.80
Revenue Per Employee	$1.23M

Feed

News

Sentiment

Earnings

Fundamentals

Info

GMABGenmab - ADR

Latest GMAB News